Blood biomarkers for differential diagnosis and early detection of pancreatic cancer.
Blood-based biomarkers
Circulating tumor DNA (ctDNA)
Circulating tumor cells
Differential diagnosis
Early detection
Liquid biopsy
Pancreatic cancer
Proteins
microRNAs
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
12
01
2021
revised:
17
03
2021
accepted:
19
03
2021
pubmed:
18
4
2021
medline:
8
5
2021
entrez:
17
4
2021
Statut:
ppublish
Résumé
Pancreatic cancer is currently the most lethal tumor entity and case numbers are rising. It will soon be the second most frequent cause of cancer-related death in the Western world. Mortality is close to incidence and patient survival after diagnosis stands at about five months. Blood-based diagnostics could be one crucial factor for improving this dismal situation and is at a stage that could make this possible. Here, we are reviewing the current state of affairs with its problems and promises, looking at various molecule types. Reported results are evaluated in the overall context. Also, we are proposing steps toward clinical utility that should advance the development toward clinical application by improving biomarker quality but also by defining distinct clinical objectives and the respective diagnostic accuracies required to achieve them. Many of the discussed points and conclusions are highly relevant to other solid tumors, too.
Identifiants
pubmed: 33865174
pii: S0305-7372(21)00041-4
doi: 10.1016/j.ctrv.2021.102193
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102193Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.